A new analysis shows that ertugliflozin matched renal results seen in trials for a pair of rival sodium glucose cotransporter 2 (SGLT2) inhibitors.
Investigators for the VERTIS-CV trial last week presented data that show ertugliflozin offers renal protective benefits on par with those of rival sodium glucose cotransporter 2 (SGLT2) inhibitors, the drug class developed for diabetes now being studied to prevent heart and kidney failure.
Ertugliflozin (Steglatro, Merck) is a relative newcomer to the SGLT2 market, which is dominated by empagliflozin (Jardiance), dapagliflozin (Farxiga), and the first drug of the class, canagliflozin (Invokana).
Five years ago, a cardiovascular outcomes trial for empagliflozin shocked scientists when it showed a 38% reduction in cardiovascular mortality; while subsequent studies have shown other SGLT2 inhibitors offer benefits in heart and renal protection, that first result has never quite been matched. And in June, the VERTIS-CV trial fell short of showing superiority in its primary and secondary end points, despite a 30% drop in heart failure hospitalization.
On Wednesday during the European Association for the Study of Diabetes virtual meeting, David Z.I. Cherney, MD, PhD, of the University of Toronto, presented new evaluations of renal data from the study:
This second evaluation is important because it matches the end point seen in the CANVAS trial for canagliflozin and the DECLARE-TIMI trial for dapagliflozin.
In addition, investigators found that the relative risk reduction for the kidney composite was similar across regardless of the patient’s stage of chronic kidney disease (CKD) or risk category, “demonstrating kidney benefits regardless of how CKD was defined.”
The study drug also significantly reduced urine albumin-to-creatinine ratio (UACR) in patients with a range of albuminuria levels, and seemed to offer the greatest benefit to those at highest risk of progressive diabetic kidney disease. Patients’ eGFR declined sharply at first, but were preserved over time.
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More